fezolinetant   Click here for help

GtoPdb Ligand ID: 10422

Synonyms: compound 3 [PMID:26191358] | ESN-364 | ESN364 | Veoza® | Veozah® | Vezoa®
Approved drug
fezolinetant is an approved drug (FDA, EMA & UK MHRA (2023))
Compound class: Synthetic organic
Comment: Fezolinetant (ESN364) is a potent and selective neurokinin (NK) receptor 3 antagonist [3]. It was developed by Astellas Pharma as a non-hormonal therapeutic option for the treatment of female sex-hormone disorders such as polycystic ovary syndrome [2] and uterine fibroids, and for the management of the vasomotor symptoms (VMS) that drive menopausal hot flashes/flushes and/or night sweats [1,8-9].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

fezolinetant is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 105.04
Molecular weight 358.1
XLogP 4.12
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES Fc1ccc(cc1)C(=O)N1CCn2c(C1C)nnc2c1snc(n1)C
Isomeric SMILES Fc1ccc(cc1)C(=O)N1CCn2c([C@H]1C)nnc2c1snc(n1)C
InChI InChI=1S/C16H15FN6OS/c1-9-13-19-20-14(15-18-10(2)21-25-15)23(13)8-7-22(9)16(24)11-3-5-12(17)6-4-11/h3-6,9H,7-8H2,1-2H3/t9-/m1/s1
InChI Key PPSNFPASKFYPMN-SECBINFHSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Depypere H, Lademacher C, Siddiqui E, Fraser GL. (2021)
Fezolinetant in the treatment of vasomotor symptoms associated with menopause.
Expert Opin Investig Drugs, 30 (7): 681-694. [PMID:33724119]
2. Fraser GL, Obermayer-Pietsch B, Laven J, Griesinger G, Pintiaux A, Timmerman D, Fauser BCJM, Lademacher C, Combalbert J, Hoveyda HR et al.. (2021)
Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
J Clin Endocrinol Metab, 106 (9): e3519-e3532. [PMID:34000049]
3. Hoveyda HR, Fraser GL, Dutheuil G, El Bousmaqui M, Korac J, Lenoir F, Lapin A, Noël S. (2015)
Optimization of Novel Antagonists to the Neurokinin-3 Receptor for the Treatment of Sex-Hormone Disorders (Part II).
ACS Med Chem Lett, 6 (7): 736-40. [PMID:26191358]
4. Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C et al.. (2023)
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
J Clin Endocrinol Metab, 108 (8): 1981-1997. [PMID:36734148]
5. Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M et al.. (2023)
Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lancet, 401 (10382): 1091-1102. [PMID:36924778]
6. Lee A. (2023)
Fezolinetant: First Approval.
Drugs, 83 (12): 1137-1141. [PMID:37462862]
7. Neal-Perry G, Cano A, Lederman S, Nappi RE, Santoro N, Wolfman W, English M, Franklin C, Valluri U, Ottery FD. (2023)
Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
Obstet Gynecol, 141 (4): 737-747. [PMID:36897180]
8. Prague JK. (2023)
Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms.
Lancet, 401 (10382): 1055-1058. [PMID:36924777]
9. Reed SD. (2024)
Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations.
Menopause, 31 (4): 245-246. [PMID:38517209]
10. Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. (2024)
Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
Menopause, 31 (4): 247-257. [PMID:38517210]